Pharmacological interventions for co-occurring psychopathology in people with borderline personality disorder: secondary analysis of the Cochrane systematic review with meta-analyses

被引:3
作者
Ribeiro, Johanne Pereira [1 ,2 ]
Juul, Sophie [3 ,4 ]
Kongerslev, Mickey T. [2 ,5 ]
Jorgensen, Mie Sedoc [1 ]
Voellm, Birgit A. [6 ]
Edemann-Callesen, Henriette [1 ]
Sales, Christian [7 ]
Schaug, Julie P. [1 ]
Lieb, Klaus [8 ]
Simonsen, Erik [9 ,10 ]
Stoffers-Winterling, Jutta M. [8 ]
Storebo, Ole Jakob [1 ,2 ]
机构
[1] Ctr Evidence Based Psychiat, Psychiat Res Unit, Psychiat Reg Zealand, Slagelse, Denmark
[2] Univ Southern Denmark, Dept Psychol, Odense, Denmark
[3] Copenhagen Univ Hospx, Ctr Clin Intervent Res, Rigshosp, Capital Reg Denmark,Copenhagen Trial Unit, Copenhagen, Denmark
[4] Copenhagen Univ Hosp, Diagnost Ctr, Copenhagen, Denmark
[5] Mental Hlth Serv West, Psychiat Reg Zealand, Slagelse, Denmark
[6] Univ Med Rostock, Chirurg, Rostock, Germany
[7] Nottinghamshire Healthcare NHS Fdn Trust, Nottingham, England
[8] Univ Med Ctr Mainz, Dept Psychiat & Psychotherapy, Mainz, Germany
[9] Copenhagen Univ Hosp, Mental Hlth Serv East, Psychiat Reg Zealand, Copenhagen, Denmark
[10] Univ Copenhagen, Fac Hlth & Med Sci, Dept Clin Med, Copenhagen, Denmark
关键词
Comorbidity; pharmaceutical drug trial; clinical trials; mental health services; personality disorders; DIALECTICAL BEHAVIOR-THERAPY; DOUBLE-BLIND; OMEGA-3-FATTY-ACID SUPPLEMENTATION; DIVALPROEX SODIUM; CLINICAL-TRIALS; PLACEBO; OLANZAPINE; CARBAMAZEPINE; WOMEN; LAMOTRIGINE;
D O I
10.1192/bjp.2024.172
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background Medications are commonly used to treat co-occurring psychopathology in persons with borderline personality disorder (BPD) Aims To systematically review and integrate the evidence of medications for treatment of co-occurring psychopathology in people with BPD, and explore the role of comorbidities. Method Building on the current Cochrane review of medications in BPD, an update literature search was done in March 2024. We followed the methods of this Cochrane review, but scrutinised all identified placebo-controlled trials post hoc for reporting of non BPD-specific ('co-occurring') psychopathology, and explored treatment effects in subgroups of samples with and without defined co-occurring disorders. GRADE ratings were done to assess the evidence certainty. Results Twenty-two trials were available for quantitative analyses. For antipsychotics, we found very-low-certainty evidence (VLCE) of an effect on depressive symptoms (standardised mean difference (SMD) -0.22, P = 0.04), and low-certainty evidence (LCE) of an effect on psychotic-dissociative symptoms (SMD -0.28, P = 0.007). There was evidence of effects of anticonvulsants on depressive (SMD -0.44, P = 0.02; LCE) and anxious symptoms (SMD -1.11, P < 0.00001; VLCE). For antidepressants, no significant findings were observed (VLCE). Exploratory subgroup analyses indicated a greater effect of antipsychotics in samples including participants with co-occurring substance use disorders on psychotic-dissociative symptoms (P = 0.001). Conclusions Our findings, based on VLCE and LCE only, do not support the use of pharmacological interventions in people with BPD to target co-occurring psychopathology. Overall, the current evidence does not support differential treatment effects in persons with versus without defined comorbidities. Medications should be used cautiously to target co-occurring psychopathology.
引用
收藏
页码:226 / 237
页数:12
相关论文
共 74 条
[1]   Omega-3 Fatty Acid Supplementation in Adolescents With Borderline Personality Disorder and Ultra-High Risk Criteria for Psychosis: A Post Hoc Subgroup Analysis of a Double-Blind, Randomized Controlled Trial [J].
Amminger, G. Paul ;
Chanen, Andrew M. ;
Ohmann, Susanne ;
Klier, Claudia M. ;
Mossaheb, Nilufar ;
Bechdolf, Andreas ;
Nelson, Barnaby ;
Thompson, Andrew ;
McGorry, Patrick D. ;
Yung, Alison R. ;
Schaefer, Miriam R. .
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2013, 58 (07) :402-408
[2]  
[Anonymous], Borderline personality disorder: recognition and management Clinical guideline CG78
[3]  
[Anonymous], 2000, Diagnostic and statistical manual of mental disorders: DSM-5, V4th, DOI [10.1176/appi.books.9780890425596, DOI 10.1176/APPI.BOOKS.9780890425596]
[4]   Comparison of Low and Moderate Dosages of Extended-Release Quetiapine in Borderline Personality Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial [J].
Black, Donald W. ;
Zanarini, Mary C. ;
Romine, Ann ;
Shaw, Martha ;
Allen, Jeff ;
Schulz, S. Charles .
AMERICAN JOURNAL OF PSYCHIATRY, 2014, 171 (11) :1174-1182
[5]  
Boehringer Ingelheim, 2024, STUDY TEST DIFFERENT
[6]  
Bogenschutz MP, 2004, J CLIN PSYCHIAT, V65, P104
[7]  
Bohus M, 2021, LANCET, V398, P1528, DOI 10.1016/S0140-6736(21)00476-1
[8]   Evaluating medical tests: introducing the Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy [J].
Bossuyt, Patrick M. ;
Deeks, Jonathan J. ;
Leeflang, Mariska M. ;
Takwoingi, Yemisi ;
Flemyng, Ella .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2023, (07)
[9]  
CORNELIUS JR, 1993, AM J PSYCHIAT, V150, P1843
[10]  
COWDRY RW, 1988, ARCH GEN PSYCHIAT, V45, P111